Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
NCT04036435
·
clinicaltrials.gov ↗
PHASE3
Phase
ACTIVE_NOT_RECRUITING
Status
1466
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
DRUG:
BMS-986165
DRUG:
Placebo
Sponsor
Bristol-Myers Squibb